Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population.

ABSTRACT:

Objective

Plasma Epstein-Barr virus (EBV) DNA is considered a biomarker for nasopharyngeal carcinoma (NPC). However, its long-term role in NPC development is unclear.

Materials and methods

A total of 1363 participants seropositive for EBV VCA-IgA and EBNA1-IgA in a community-based NPC screening program in southern China were tested for plasma EBV DNA levels by real-time qPCR between 2008 and 2015. New NPC cases were confirmed by active follow-up approach and linkage to local cancer registry through the end of 2016. Cox proportional hazards regression analysis was performed to calculate the hazard ratios (HRs) for NPC risk with plasma EBV DNA.

Results

Thirty patients were newly diagnosed during a median 7.5 years follow-up. NPC incidence increased with the plasma EBV D

SUBMITTER: Chen WJ 

PROVIDER: S-EPMC8168313 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature